VIGUEN MOVSESIAN: Open Payments
NPI 1477548923 · LOS ANGELES, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$693 in 12 payments from 4 companies in 2025. Trend: 2023 $411 · 2024 $112 · 2025 $693
Food & beverage: $470Education: $223
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 4 | $451 |
| Neurocrine BioSciences, Inc. | 5 | $138 |
| E.R. Squibb & Sons, L.L.C. | 2 | $82 |
| Luye Pharma (USA) Ltd. | 1 | $23 |
Products named: UZEDY, INGREZZA, COBENFY, ERZOFRI EXTENDED-RELEASE.
Industry payments across CA — which companies pay providers there.
